[go: up one dir, main page]

MA37524B1 - Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee - Google Patents

Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee

Info

Publication number
MA37524B1
MA37524B1 MA37524A MA37524A MA37524B1 MA 37524 B1 MA37524 B1 MA 37524B1 MA 37524 A MA37524 A MA 37524A MA 37524 A MA37524 A MA 37524A MA 37524 B1 MA37524 B1 MA 37524B1
Authority
MA
Morocco
Prior art keywords
chloride content
anamoreline
hydrochloride
producing
methods
Prior art date
Application number
MA37524A
Other languages
English (en)
Other versions
MA37524A1 (fr
Inventor
Rubio Silvina Garcia
Peter Manini
Shin-Itsu Kuwabe
Takehiko Yanagimachi
Hideyuki Yoshiyama
Groot Eleanor De
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37524(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA37524A1 publication Critical patent/MA37524A1/fr
Publication of MA37524B1 publication Critical patent/MA37524B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des formes particulaires de monochlorhydrate d'anamoréline, ou une composition contenant du monochlorhydrate d'anamoréline présentant une teneur en chlorure régulée, de préférence isolé sous une forme particulaire fine et/ou amorphe, des procédés de préparation des formes particulaires, ainsi que des compositions pharmaceutiques contenant les formes particulaires.
MA37524A 2012-04-20 2013-04-18 Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee MA37524B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
PCT/US2013/037159 WO2013158874A1 (fr) 2012-04-20 2013-04-18 Procédés de production de chlorhydrate d'anamoréline présentant une teneur en chlorure régulée

Publications (2)

Publication Number Publication Date
MA37524A1 MA37524A1 (fr) 2016-06-30
MA37524B1 true MA37524B1 (fr) 2017-04-28

Family

ID=48225135

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37524A MA37524B1 (fr) 2012-04-20 2013-04-18 Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee

Country Status (47)

Country Link
US (8) US20140018391A1 (fr)
EP (3) EP3517532B1 (fr)
JP (3) JP6109925B2 (fr)
KR (2) KR102141323B1 (fr)
CN (3) CN110041398A (fr)
AP (1) AP2014008013A0 (fr)
AR (1) AR090725A1 (fr)
AU (1) AU2013249197B2 (fr)
BR (1) BR112014025972A8 (fr)
CA (2) CA3031652C (fr)
CL (1) CL2014002817A1 (fr)
CO (1) CO7131356A2 (fr)
CR (1) CR20140530A (fr)
CY (1) CY1120276T1 (fr)
DK (2) DK3517532T3 (fr)
DO (1) DOP2014000235A (fr)
EA (1) EA031581B1 (fr)
EC (1) ECSP14027739A (fr)
ES (2) ES2658862T3 (fr)
GE (2) GEP20186902B (fr)
HK (1) HK1248694A1 (fr)
HR (1) HRP20180316T1 (fr)
HU (2) HUE035697T2 (fr)
IL (1) IL235064B (fr)
JO (1) JO3353B1 (fr)
LT (1) LT2838892T (fr)
MA (1) MA37524B1 (fr)
MD (1) MD4615C1 (fr)
ME (1) ME02966B (fr)
MX (1) MX354793B (fr)
MY (1) MY170068A (fr)
NI (1) NI201400124A (fr)
NO (1) NO2877697T3 (fr)
NZ (1) NZ700833A (fr)
PE (1) PE20150084A1 (fr)
PH (1) PH12014502351B1 (fr)
PL (2) PL2838892T3 (fr)
PT (2) PT2838892T (fr)
RS (1) RS56869B1 (fr)
SG (2) SG11201406478XA (fr)
SI (2) SI2838892T1 (fr)
TN (1) TN2014000421A1 (fr)
TW (2) TWI677494B (fr)
UA (1) UA116207C2 (fr)
UY (1) UY34753A (fr)
WO (1) WO2013158874A1 (fr)
ZA (1) ZA201408508B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
US9675600B2 (en) * 2014-09-04 2017-06-13 Helsinn Healthcare Sa Medical treatments based on anamorelin
KR20180030825A (ko) 2015-07-24 2018-03-26 뉴링크 제네틱스 코퍼레이션 1-메틸-d-트립토판의 염 및 프로드러그
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
WO2021038519A1 (fr) 2019-08-30 2021-03-04 Helsinn Healthcare Sa Procédés de fabrication de comprimés d'anamoréline présentant une stabilité améliorée

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73530C2 (uk) * 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
WO2005030698A1 (fr) * 2003-09-26 2005-04-07 Ranbaxy Laboratories Limited Procede de preparation de voglibose
EP2298760B1 (fr) 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Formes cristallines d'acide (3R)-1-2-méthylalanyl-D-tryptophyl)-3-(phénylméthyl)-3-pipéridinecarboxylic 1,2,2-triméthylhydrazide
CN101686966A (zh) * 2007-02-13 2010-03-31 赫尔辛医疗（美国）有限公司 使用生长激素促分泌素治疗细胞增生疾病的方法
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Also Published As

Publication number Publication date
CL2014002817A1 (es) 2015-08-14
MD4615C1 (ro) 2019-08-31
NZ700833A (en) 2016-01-29
HUE035697T2 (en) 2018-05-28
US20160237115A1 (en) 2016-08-18
EP3290410B1 (fr) 2020-07-01
KR20150013115A (ko) 2015-02-04
ME02966B (fr) 2018-07-20
SI3290410T1 (sl) 2020-11-30
US10905737B2 (en) 2021-02-02
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
US20160229889A1 (en) 2016-08-11
ES2820354T3 (es) 2021-04-20
CA3031652A1 (fr) 2013-10-24
CO7131356A2 (es) 2014-12-01
CN110041304A (zh) 2019-07-23
MD20140122A2 (ro) 2015-05-31
IL235064B (en) 2019-09-26
PL3290410T3 (pl) 2021-01-11
US20190231843A1 (en) 2019-08-01
US20200276259A1 (en) 2020-09-03
US20190000914A1 (en) 2019-01-03
US9872883B2 (en) 2018-01-23
CN103857669B (zh) 2019-06-28
CY1120276T1 (el) 2019-07-10
DK2838892T3 (en) 2018-03-12
NO2877697T3 (fr) 2018-10-13
MA37524A1 (fr) 2016-06-30
RS56869B1 (sr) 2018-04-30
PH12014502351A1 (en) 2015-01-12
NI201400124A (es) 2015-09-21
US10576122B2 (en) 2020-03-03
AP2014008013A0 (en) 2014-10-31
MY170068A (en) 2019-07-03
US10300105B2 (en) 2019-05-28
PT3517532T (pt) 2021-11-08
EP2838892A1 (fr) 2015-02-25
JP2015514779A (ja) 2015-05-21
GEP20186902B (en) 2018-10-25
US9403867B2 (en) 2016-08-02
US9981002B2 (en) 2018-05-29
UY34753A (es) 2013-11-29
DOP2014000235A (es) 2015-01-31
LT2838892T (lt) 2018-03-12
CA2869893A1 (fr) 2013-10-24
EA201401151A1 (ru) 2015-06-30
EA031581B1 (ru) 2019-01-31
ES2658862T3 (es) 2018-03-12
UA116207C2 (uk) 2018-02-26
HK1202863A1 (en) 2015-10-09
BR112014025972A2 (pt) 2017-06-27
US9956261B2 (en) 2018-05-01
PH12014502351B1 (en) 2015-01-12
JO3353B1 (ar) 2019-03-13
DK3517532T3 (da) 2022-01-03
WO2013158874A1 (fr) 2013-10-24
GEAP201813634A (en) 2018-06-25
AU2013249197A1 (en) 2014-10-30
PL2838892T3 (pl) 2018-05-30
CA2869893C (fr) 2019-03-05
JP6616853B2 (ja) 2019-12-04
HK1248694A1 (en) 2018-10-19
KR102141323B1 (ko) 2020-08-05
SI2838892T1 (en) 2018-05-31
HUE050865T2 (hu) 2021-01-28
KR101972998B1 (ko) 2019-04-29
EP3517532B1 (fr) 2021-10-13
US20150072934A1 (en) 2015-03-12
MX2014012178A (es) 2015-08-05
BR112014025972A8 (pt) 2021-06-22
IL235064A0 (en) 2014-12-31
HRP20180316T1 (hr) 2018-04-06
EP2838892B1 (fr) 2017-12-06
TW201348224A (zh) 2013-12-01
JP2018076375A (ja) 2018-05-17
MX354793B (es) 2018-03-21
CN110041398A (zh) 2019-07-23
JP2017101082A (ja) 2017-06-08
TWI677494B (zh) 2019-11-21
PT2838892T (pt) 2018-02-28
TN2014000421A1 (en) 2016-03-30
TW201722928A (zh) 2017-07-01
AR090725A1 (es) 2014-12-03
CN103857669A (zh) 2014-06-11
KR20190044697A (ko) 2019-04-30
EP3290410A1 (fr) 2018-03-07
CR20140530A (es) 2015-03-25
PE20150084A1 (es) 2015-01-23
TWI589572B (zh) 2017-07-01
US20140018391A1 (en) 2014-01-16
JP6109925B2 (ja) 2017-04-05
CA3031652C (fr) 2020-10-27
AU2013249197B2 (en) 2017-04-06
SG11201406478XA (en) 2014-11-27
SG10201608488RA (en) 2016-12-29
US20160235804A1 (en) 2016-08-18
EP3517532A1 (fr) 2019-07-31
ECSP14027739A (es) 2015-12-31
JP6284665B2 (ja) 2018-02-28

Similar Documents

Publication Publication Date Title
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
NZ716487A (en) Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
MX357305B (es) Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
MA35567B1 (fr) Nouvelle formulation de méloxicam
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MA33299B1 (fr) Nouvelle formulation de naproxène
AU2012258977A8 (en) Inhibitors of LRRK2 kinase activity
MA33295B1 (fr) Nouvelle formulation de diclofénac
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
TW200619220A (en) New hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5, 6, 7, 8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-mithoxy-n-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
MA33838B1 (fr) Forme amorphe et cristalline de l'hémitartrate de genz 112638 au titre d'inhibiteur de la glucosylcéramide synthétase
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
MA33296B1 (fr) Nouvelle formulation d'indométhacine
MX2009009592A (es) Aminopiridinas utiles como inhibidores de proteinas cinasas.
MX2009006345A (es) Compuestos utiles como inhibidores de proteina cinasa.
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
GB2511685A (en) Muscarinic m1 receptor agonists
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
EA200702329A1 (ru) Замещенные пирролпиридины, содержащие их композиции, способ получения и применение
MA37666B1 (fr) Sel de camsylate
MA37524B1 (fr) Procedes de production de chlorhydrate d'anamoreline presentant une teneur en chlorure regulee
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych